210 related articles for article (PubMed ID: 10029076)
1. 1,25-Dihydroxyvitamin D3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage.
Ravid A; Rocker D; Machlenkin A; Rotem C; Hochman A; Kessler-Icekson G; Liberman UA; Koren R
Cancer Res; 1999 Feb; 59(4):862-7. PubMed ID: 10029076
[TBL] [Abstract][Full Text] [Related]
2. Vitamin D is a prooxidant in breast cancer cells.
Koren R; Hadari-Naor I; Zuck E; Rotem C; Liberman UA; Ravid A
Cancer Res; 2001 Feb; 61(4):1439-44. PubMed ID: 11245448
[TBL] [Abstract][Full Text] [Related]
3. 1alpha,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells.
Swami S; Krishnan AV; Feldman D
Clin Cancer Res; 2000 Aug; 6(8):3371-9. PubMed ID: 10955825
[TBL] [Abstract][Full Text] [Related]
4. 1,25-Dihydroxyvitamin D3 and all-trans-retinoic acid sensitize breast cancer cells to chemotherapy-induced cell death.
Wang Q; Yang W; Uytingco MS; Christakos S; Wieder R
Cancer Res; 2000 Apr; 60(7):2040-8. PubMed ID: 10766196
[TBL] [Abstract][Full Text] [Related]
5. Combined effects of 1,25-dihydroxyvitamin D3 and platinum drugs on the growth of MCF-7 cells.
Cho YL; Christensen C; Saunders DE; Lawrence WD; Deppe G; Malviya VK; Malone JM
Cancer Res; 1991 Jun; 51(11):2848-53. PubMed ID: 2032225
[TBL] [Abstract][Full Text] [Related]
6. Antioxidants and doxorubicin supplementation to modulate CD14 expression and oxidative stress induced by vitamin D3 and seocalcitol in HL60 cells.
Bondza-Kibangou P; Millot C; El Khoury V; Millot JM
Oncol Rep; 2007 Dec; 18(6):1513-9. PubMed ID: 17982638
[TBL] [Abstract][Full Text] [Related]
7. The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression.
Campbell MJ; Gombart AF; Kwok SH; Park S; Koeffler HP
Oncogene; 2000 Oct; 19(44):5091-7. PubMed ID: 11042697
[TBL] [Abstract][Full Text] [Related]
8. The novel analog 1,24(S)-dihydroxyvitamin D2 is as equipotent as 1,25-dihydroxyvitamin D3 in growth regulation of cancer cell lines.
Levy Y; Knutson JC; Bishop C; Shany S
Anticancer Res; 1998; 18(3A):1769-75. PubMed ID: 9673403
[TBL] [Abstract][Full Text] [Related]
9. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
Chen TC; Schwartz GG; Burnstein KL; Lokeshwar BL; Holick MF
Clin Cancer Res; 2000 Mar; 6(3):901-8. PubMed ID: 10741714
[TBL] [Abstract][Full Text] [Related]
10. Biochemical significance of enhanced activity of fluorinated 1,25-dihydroxyvitamin D3 in human cultured cell lines.
Eisman JA; Frampton RJ; McLean FJ
Cell Biochem Funct; 1986 Apr; 4(2):115-22. PubMed ID: 3011306
[TBL] [Abstract][Full Text] [Related]
11. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of serum-stimulated mitogen activated protein kinase by 1alpha,25(OH)2-vitamin D3 in MCF-7 breast cancer cells.
Capiati DA; Rossi AM; Picotto G; Benassati S; Boland RL
J Cell Biochem; 2004 Oct; 93(2):384-97. PubMed ID: 15368364
[TBL] [Abstract][Full Text] [Related]
13. Vitamin D sensitizes breast cancer cells to the action of H2O2: mitochondria as a convergence point in the death pathway.
Weitsman GE; Koren R; Zuck E; Rotem C; Liberman UA; Ravid A
Free Radic Biol Med; 2005 Jul; 39(2):266-78. PubMed ID: 15964518
[TBL] [Abstract][Full Text] [Related]
14. Amphiregulin is a vitamin D3 target gene in squamous cell and breast carcinoma.
Akutsu N; Bastien Y; Lin R; Mader S; White JH
Biochem Biophys Res Commun; 2001 Mar; 281(4):1051-6. PubMed ID: 11237771
[TBL] [Abstract][Full Text] [Related]
15. Estrogen-induced potentiation of DNA damage and cytotoxicity in human breast cancer cells treated with topoisomerase II-interactive antitumor drugs.
Epstein RJ; Smith PJ
Cancer Res; 1988 Jan; 48(2):297-303. PubMed ID: 2825970
[TBL] [Abstract][Full Text] [Related]
16. 5,6-trans-16-ene-vitamin D3: a new class of potent inhibitors of proliferation of prostate, breast, and myeloid leukemic cells.
Hisatake J; Kubota T; Hisatake Y; Uskokovic M; Tomoyasu S; Koeffler HP
Cancer Res; 1999 Aug; 59(16):4023-9. PubMed ID: 10463602
[TBL] [Abstract][Full Text] [Related]
17. The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity.
Swift LP; Cutts SM; Nudelman A; Levovich I; Rephaeli A; Phillips DR
Cancer Chemother Pharmacol; 2008 Apr; 61(5):739-49. PubMed ID: 17594094
[TBL] [Abstract][Full Text] [Related]
18. Contributions of pro-oxidant and anti-oxidant conditions to the actions of 24,25-dihydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 on phosphate uptake in intestinal cells.
Peery SL; Nemere I
J Cell Biochem; 2007 Aug; 101(5):1176-84. PubMed ID: 17226781
[TBL] [Abstract][Full Text] [Related]
19. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
Koike M; Koshizuka K; Kawabata H; Yang R; Taub HE; Said J; Uskokovic M; Tsuruoka N; Koeffler HP
Anticancer Res; 1999; 19(3A):1689-97. PubMed ID: 10470102
[TBL] [Abstract][Full Text] [Related]
20. Enhancing the antiproliferative effect of topoisomerase II inhibitors using a polypeptide inhibitor of c-Myc.
Bidwell GL; Raucher D
Biochem Pharmacol; 2006 Jan; 71(3):248-56. PubMed ID: 16316634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
